APO Research
Talk to an analyst

APO RESEARCH · REPORT

Virus like Particle (VLP) Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Virus like Particle (VLP) Vaccines Industry Growth and Trends Forecast to 2032

28 December 2025107 pages

Choose your research edition.

Industry ResearchVirus like Particle (VLP) Vaccines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus like Particle (VLP) Vaccines Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Virus like Particle (VLP) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus like Particle (VLP) Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus like Particle (VLP) Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Virus like Particle (VLP) Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Virus like Particle (VLP) Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Virus like Particle (VLP) Vaccines market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Virus like Particle (VLP) Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Virus like Particle (VLP) Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Virus like Particle (VLP) Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Virus like Particle (VLP) Vaccines Market by Company

WuXi Biologics

Junshi Biosciences

Luye Pharma Group

Chengdu Kanghua Biological Products Co., Ltd.

Shanghai Bovax Biotechnology Co., Ltd.

VBI Vaccines Inc

Premas Biotech

Creative Diagnostics

Creative Biostructure

Coriolis

Charles River Laboratories

BioAgilytix

AstraZeneca Group (Icosavax)

Virus like Particle (VLP) Vaccines Segment by Type

Prophylactic Vaccine

Therapeutic Vaccine

Virus like Particle (VLP) Vaccines Segment by Application

Human Papillomavirus (HPV)

Hepatitis E Virus (HEV)

Hepatitis B Virus (HBV)

Other

Virus like Particle (VLP) Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Prophylactic Vaccine Table 2. Major Company of Therapeutic Vaccine Table 3. Global Virus like Particle (VLP) Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 5. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type (2021-2026) Table 6. Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 7. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type (2021-2026) Table 8. Global Virus like Particle (VLP) Vaccines Price by Type (2021-2026) & (US$/Unit) Table 9. Global Virus like Particle (VLP) Vaccines Sales by Type (2027-2032) & (K Units) Table 10. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type (2027-2032) Table 11. Global Virus like Particle (VLP) Vaccines Sales by Type (2027-2032) & (US$ Million) Table 12. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type (2027-2032) Table 13. Global Virus like Particle (VLP) Vaccines Price by Type (2027-2032) & (US$/Unit) Table 14. North America Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 15. North America Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 17. Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 21. Latin America Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (US$ Million) Table 24. Virus like Particle (VLP) Vaccines Industry Trends Table 25. Virus like Particle (VLP) Vaccines Industry Drivers Table 26. Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges Table 27. Virus like Particle (VLP) Vaccines Industry Restraints Table 28. Global Virus like Particle (VLP) Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company (2021-2026) Table 30. Global Virus like Particle (VLP) Vaccines Sales by Company (2021-2026) & (K Units) Table 31. Global Virus like Particle (VLP) Vaccines Sales Share by Company (2021-2026) Table 32. Global Virus like Particle (VLP) Vaccines Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Virus like Particle (VLP) Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Virus like Particle (VLP) Vaccines Major Company Production Sites and Headquarters Table 35. Global Virus like Particle (VLP) Vaccines Company, Product Type & Application Table 36. Global Virus like Particle (VLP) Vaccines Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Virus like Particle (VLP) Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Virus like Particle (VLP) Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (K Units) Table 41. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Region (2021-2026) Table 42. Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (US$ Million) Table 43. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Region (2021-2026) Table 44. Global Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Virus like Particle (VLP) Vaccines Sales by Region (2027-2032) & (K Units) Table 46. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Region (2027-2032) Table 47. Global Virus like Particle (VLP) Vaccines Sales by Region (2027-2032) & (US$ Million) Table 48. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Region (2027-2032) Table 49. Global Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Virus like Particle (VLP) Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 52. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application (2021-2026) Table 53. Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 54. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application (2021-2026) Table 55. Global Virus like Particle (VLP) Vaccines Price by Application (2021-2026) & (US$/Unit) Table 56. Global Virus like Particle (VLP) Vaccines Sales by Application (2027-2032) & (K Units) Table 57. Global Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application (2027-2032) Table 58. Global Virus like Particle (VLP) Vaccines Sales by Application (2027-2032) & (US$ Million) Table 59. Global Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application (2027-2032) Table 60. Global Virus like Particle (VLP) Vaccines Price by Application (2027-2032) & (US$/Unit) Table 61. North America Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 62. North America Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 64. Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 68. Latin America Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (US$ Million) Table 71. WuXi Biologics Company Information Table 72. WuXi Biologics Business Overview Table 73. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio Table 75. WuXi Biologics Recent Development Table 76. Junshi Biosciences Company Information Table 77. Junshi Biosciences Business Overview Table 78. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio Table 80. Junshi Biosciences Recent Development Table 81. Luye Pharma Group Company Information Table 82. Luye Pharma Group Business Overview Table 83. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio Table 85. Luye Pharma Group Recent Development Table 86. Chengdu Kanghua Biological Products Co., Ltd. Company Information Table 87. Chengdu Kanghua Biological Products Co., Ltd. Business Overview Table 88. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 90. Chengdu Kanghua Biological Products Co., Ltd. Recent Development Table 91. Shanghai Bovax Biotechnology Co., Ltd. Company Information Table 92. Shanghai Bovax Biotechnology Co., Ltd. Business Overview Table 93. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 95. Shanghai Bovax Biotechnology Co., Ltd. Recent Development Table 96. VBI Vaccines Inc Company Information Table 97. VBI Vaccines Inc Business Overview Table 98. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio Table 100. VBI Vaccines Inc Recent Development Table 101. Premas Biotech Company Information Table 102. Premas Biotech Business Overview Table 103. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio Table 105. Premas Biotech Recent Development Table 106. Creative Diagnostics Company Information Table 107. Creative Diagnostics Business Overview Table 108. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio Table 110. Creative Diagnostics Recent Development Table 111. Creative Biostructure Company Information Table 112. Creative Biostructure Business Overview Table 113. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio Table 115. Creative Biostructure Recent Development Table 116. Coriolis Company Information Table 117. Coriolis Business Overview Table 118. Coriolis Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Coriolis Virus like Particle (VLP) Vaccines Product Portfolio Table 120. Coriolis Recent Development Table 121. Charles River Laboratories Company Information Table 122. Charles River Laboratories Business Overview Table 123. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio Table 125. Charles River Laboratories Recent Development Table 126. BioAgilytix Company Information Table 127. BioAgilytix Business Overview Table 128. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio Table 130. BioAgilytix Recent Development Table 131. AstraZeneca Group (Icosavax) Company Information Table 132. AstraZeneca Group (Icosavax) Business Overview Table 133. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio Table 135. AstraZeneca Group (Icosavax) Recent Development Table 136. North America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. North America Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 138. North America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 139. North America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 140. North America Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Country (2027-2032) Table 141. North America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. North America Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 143. North America Virus like Particle (VLP) Vaccines Market Share by Country (2021-2026) Table 144. North America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. North America Virus like Particle (VLP) Vaccines Market Share Forecast by Country (2027-2032) Table 146. Europe Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 148. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 149. Europe Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 150. Europe Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Country (2027-2032) Table 151. Europe Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Europe Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 153. Europe Virus like Particle (VLP) Vaccines Market Share by Country (2021-2026) Table 154. Europe Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Europe Virus like Particle (VLP) Vaccines Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 158. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 159. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 160. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 163. Asia-Pacific Virus like Particle (VLP) Vaccines Market Share by Country (2021-2026) Table 164. Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Asia-Pacific Virus like Particle (VLP) Vaccines Market Share Forecast by Country (2027-2032) Table 166. Latin America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Latin America Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 168. Latin America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 169. Latin America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 170. Latin America Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Country (2027-2032) Table 171. Latin America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Latin America Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 173. Latin America Virus like Particle (VLP) Vaccines Market Share by Country (2021-2026) Table 174. Latin America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Latin America Virus like Particle (VLP) Vaccines Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 178. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 179. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 183. Middle East and Africa Virus like Particle (VLP) Vaccines Market Share by Country (2021-2026) Table 184. Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Middle East and Africa Virus like Particle (VLP) Vaccines Market Share Forecast by Country (2027-2032) Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Virus like Particle (VLP) Vaccines Distributors List Table 189. Virus like Particle (VLP) Vaccines Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Virus like Particle (VLP) Vaccines Image Figure 2. Global Virus like Particle (VLP) Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus like Particle (VLP) Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Virus like Particle (VLP) Vaccines Sales (2021-2032) & (K Units) Figure 5. Prophylactic Vaccine Image Figure 6. Global Prophylactic Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Therapeutic Vaccine Image Figure 8. Global Therapeutic Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Virus like Particle (VLP) Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Virus like Particle (VLP) Vaccines Market Share by Type 2025 VS 2032 Figure 11. North America Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type in 2025 Figure 12. North America Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type in 2025 Figure 13. Europe Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. Europe Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Latin America Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Human Papillomavirus (HPV) Image Figure 24. Global Human Papillomavirus (HPV) Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hepatitis E Virus (HEV) Image Figure 26. Global Hepatitis E Virus (HEV) Sales YoY Growth (2021-2032) & (K Units) Figure 27. Hepatitis B Virus (HBV) Image Figure 28. Global Hepatitis B Virus (HBV) Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Virus like Particle (VLP) Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Virus like Particle (VLP) Vaccines Market Share by Application 2025 VS 2032 Figure 33. North America Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. North America Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Europe Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Europe Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Latin America Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share in Value by Application in 2025 Figure 43. North America Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Virus like Particle (VLP) Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Virus like Particle (VLP) Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Virus like Particle (VLP) Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Virus like Particle (VLP) Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Virus like Particle (VLP) Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Virus like Particle (VLP) Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Virus like Particle (VLP) Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Virus like Particle (VLP) Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Virus like Particle (VLP) Vaccines Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Virus like Particle (VLP) Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Prophylactic Vaccine
  • Therapeutic Vaccine
Applications
  • Human Papillomavirus (HPV)
  • Hepatitis E Virus (HEV)
  • Hepatitis B Virus (HBV)
  • Other
Companies covered
  • WuXi Biologics
  • Junshi Biosciences
  • Luye Pharma Group
  • Chengdu Kanghua Biological Products Co., Ltd.
  • Shanghai Bovax Biotechnology Co., Ltd.
  • VBI Vaccines Inc
  • Premas Biotech
  • Creative Diagnostics
  • Creative Biostructure
  • Coriolis
  • Charles River Laboratories
  • BioAgilytix
  • AstraZeneca Group (Icosavax)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Virus like Particle (VLP) Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Virus like Particle (VLP) Vaccines Market by Type
  6. 1.3.1 Prophylactic Vaccine
  7. 1.3.2 Therapeutic Vaccine
  8. 1.4 Global Virus like Particle (VLP) Vaccines Market Size by Type
  9. 1.4.1 Global Virus like Particle (VLP) Vaccines Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Virus like Particle (VLP) Vaccines Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Virus like Particle (VLP) Vaccines Industry Trends
  2. 2.2 Virus like Particle (VLP) Vaccines Industry Drivers
  3. 2.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
  4. 2.4 Virus like Particle (VLP) Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Virus like Particle (VLP) Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Virus like Particle (VLP) Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Virus like Particle (VLP) Vaccines Price (2021-2026)
  4. 3.4 Global Virus like Particle (VLP) Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Virus like Particle (VLP) Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Virus like Particle (VLP) Vaccines Company, Product Type & Application
  7. 3.7 Global Virus like Particle (VLP) Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Virus like Particle (VLP) Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Virus like Particle (VLP) Vaccines Tier 1, Tier 2, and Tier 3
4 Virus like Particle (VLP) Vaccines Regional Status and Outlook
  1. 4.1 Global Virus like Particle (VLP) Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Virus like Particle (VLP) Vaccines Historic Market Size by Region
  3. 4.2.1 Global Virus like Particle (VLP) Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Virus like Particle (VLP) Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Virus like Particle (VLP) Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Virus like Particle (VLP) Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Virus like Particle (VLP) Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Virus like Particle (VLP) Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Virus like Particle (VLP) Vaccines by Application
  1. 5.1 Virus like Particle (VLP) Vaccines Market by Application
  2. 5.1.1 Human Papillomavirus (HPV)
  3. 5.1.2 Hepatitis E Virus (HEV)
  4. 5.1.3 Hepatitis B Virus (HBV)
  5. 5.1.4 Other
  6. 5.2 Global Virus like Particle (VLP) Vaccines Market Size by Application
  7. 5.2.1 Global Virus like Particle (VLP) Vaccines Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Virus like Particle (VLP) Vaccines Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 WuXi Biologics
  2. 6.1.1 WuXi Biologics Company Information
  3. 6.1.2 WuXi Biologics Business Overview
  4. 6.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
  6. 6.1.5 WuXi Biologics Recent Developments
  7. 6.2 Junshi Biosciences
  8. 6.2.1 Junshi Biosciences Company Information
  9. 6.2.2 Junshi Biosciences Business Overview
  10. 6.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
  12. 6.2.5 Junshi Biosciences Recent Developments
  13. 6.3 Luye Pharma Group
  14. 6.3.1 Luye Pharma Group Company Information
  15. 6.3.2 Luye Pharma Group Business Overview
  16. 6.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
  18. 6.3.5 Luye Pharma Group Recent Developments
  19. 6.4 Chengdu Kanghua Biological Products Co., Ltd.
  20. 6.4.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
  21. 6.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
  22. 6.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  24. 6.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
  25. 6.5 Shanghai Bovax Biotechnology Co., Ltd.
  26. 6.5.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
  27. 6.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
  28. 6.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  30. 6.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
  31. 6.6 VBI Vaccines Inc
  32. 6.6.1 VBI Vaccines Inc Company Information
  33. 6.6.2 VBI Vaccines Inc Business Overview
  34. 6.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
  36. 6.6.5 VBI Vaccines Inc Recent Developments
  37. 6.7 Premas Biotech
  38. 6.7.1 Premas Biotech Company Information
  39. 6.7.2 Premas Biotech Business Overview
  40. 6.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
  42. 6.7.5 Premas Biotech Recent Developments
  43. 6.8 Creative Diagnostics
  44. 6.8.1 Creative Diagnostics Company Information
  45. 6.8.2 Creative Diagnostics Business Overview
  46. 6.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
  48. 6.8.5 Creative Diagnostics Recent Developments
  49. 6.9 Creative Biostructure
  50. 6.9.1 Creative Biostructure Company Information
  51. 6.9.2 Creative Biostructure Business Overview
  52. 6.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
  54. 6.9.5 Creative Biostructure Recent Developments
  55. 6.10 Coriolis
  56. 6.10.1 Coriolis Company Information
  57. 6.10.2 Coriolis Business Overview
  58. 6.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
  60. 6.10.5 Coriolis Recent Developments
  61. 6.11 Charles River Laboratories
  62. 6.11.1 Charles River Laboratories Company Information
  63. 6.11.2 Charles River Laboratories Business Overview
  64. 6.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
  66. 6.11.5 Charles River Laboratories Recent Developments
  67. 6.12 BioAgilytix
  68. 6.12.1 BioAgilytix Company Information
  69. 6.12.2 BioAgilytix Business Overview
  70. 6.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
  72. 6.12.5 BioAgilytix Recent Developments
  73. 6.13 AstraZeneca Group (Icosavax)
  74. 6.13.1 AstraZeneca Group (Icosavax) Company Information
  75. 6.13.2 AstraZeneca Group (Icosavax) Business Overview
  76. 6.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
  78. 6.13.5 AstraZeneca Group (Icosavax) Recent Developments
7 North America by Country
  1. 7.1 North America Virus like Particle (VLP) Vaccines Sales by Country
  2. 7.1.1 North America Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Virus like Particle (VLP) Vaccines Market Size by Country
  6. 7.2.1 North America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Virus like Particle (VLP) Vaccines Sales by Country
  2. 8.1.1 Europe Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Virus like Particle (VLP) Vaccines Market Size by Country
  6. 8.2.1 Europe Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Virus like Particle (VLP) Vaccines Sales by Country
  2. 10.1.1 South America Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Virus like Particle (VLP) Vaccines Market Size by Country
  6. 10.2.1 South America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
  2. 12.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Virus like Particle (VLP) Vaccines Production Mode & Process
  7. 12.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Virus like Particle (VLP) Vaccines Distributors
  10. 12.2.3 Virus like Particle (VLP) Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst